Possible Interaction: Vitamin D and Paricalcitol

“ Cholecalciferol treatment significantly increased serum 25(OH)D levels, significantly decreased PTH levels and paricalcitol doses , concurrently entailing a better control of anemia.”

“On subgroup analysis, any calcidiol treatment or calcidiol combined with paricalcitol associated with significantly higher mortality rates than no treatment (47% and 62.5%, p = 0.043 and 0.008, respectively).”

“Conclusions: Cholecalciferol , in combination with paricalcitol , additively lowers the iPTH levels in a significant number of patients after 16 weeks of supplementation.”

“Hospitalization rate was similar in two arms; however, ergocalciferol treatment inversely associated with paricalcitol dose (β ± SE = −10.4 ± 2.8; p < 0.001).ConclusionsOne-year of ergocalciferol supplementation was not associated with reduction in EPO requirement or hospitalization rate in HD patients with VDD.”

“Both treatment with paricalcitol and with calcifediol produced a significant decrease in levels of IL-8 (P<.001), a known inflammatory marker, drawing attention to a trend towards better response to erythropoiesis-stimulating agents (ESAs), possibly related to the decrease in inflammation.”

“ Paricalcitol significantly reduced serum …-dihydroxyvitamin D, and 25-hydroxyvitamin D while significantly increasing serum concentrations of fibroblast growth factor-23 and 24,25-dihydroxyvitamin D. Paricalcitol, however, had no significant … primary outcome measure), insulin sensitivity, beta-cell insulin response, plasma free fatty acid suppression, or urinary F2-isoprostane excretion.”

“ Vitamin D use has increased and parallels the rise in use of paricalcitol and doxercalciferol.”

“Initiating vitamin D therapy with paricalcitol may result in overall savings of approximately 7600-11,000 US dollars per patient per year.”

“ Vitamin D3 pretreatment and paricalcitol led to an important delay in the onset of penicillin-induced epileptiform activity (p < 0.001 and p < 0.05, respectively).”

“In … with paricalcitol markedly down-regulated the expression of TLR4, …-α and NF-κB. Conclusions The vitamin D analogue paricalcitol attenuates hepatic I/R injury through down-regulation of the TLR4 signaling pathway and … considered to be a potential nutritional therapeutic agent against I/R injury in the liver.”